<DOC>
	<DOCNO>NCT00756509</DOCNO>
	<brief_summary>The purpose multicenter , single-arm , exact binomial single-stage , phase II trial evaluate efficacy Nilotinib patient unresectable metastatic gastrointestinal stromal tumor</brief_summary>
	<brief_title>Treatment Patients With Metastatic Unresectable Gastrointestinal Stromal Tumors First Line With Nilotinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Age ≥18 year Histologically confirm diagnosis GIST unresectable and/or metastatic therefore amenable surgery combine modality curative intent prior Visit 1 At least one measurable site disease CT/MRI scan Visit 1 , define RECIST criterion ( see Post Text Suppl 3 detail ) The scan maximum 2 week old . New scan require baseline scan older approx . 2 week . WHO Performance Status 0 , 1 2 Patients must follow laboratory value ( ≥ LLN ( low limit normal ) correct within normal limit supplement prior first dose study medication . ) : 1 . Potassium ≥ LLN , 2 . Magnesium ≥ LLN , 3 . Phosphorus ≥ LLN , 4 . Total calcium ( correct serum albumin ) ≥ LLN Patients must normal organ , electrolyte , marrow function define : 1 . Absolute Neutrophil Count ( ANC ) ≥ 1.5x 109/L ; 2 . Platelets ≥ 100 x 109/L ; 3 . ALT AST ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x ULN consider due tumor ; 4 . Alkaline phosphatase ≤ 2.5 x ULN unless consider due tumor ; 5 . Serum bilirubin ≤ 1.5 x ULN ; 6 . Serum lipase amylase ≤ 1.5 x ULN ; 7 . Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min . ( calculated creatinine clearance use Cockroft formula acceptable ) Ability understand willingness sign write informed consent Prior treatment nilotinib Treatment cytotoxic and/or investigational cytotoxic drug ≤ 4 week ( 6 week nitrosurea mitomycin C ) prior Visit 1 exception imatinib target therapy adjuvant therapy Prior concomitant malignancy require active treatment GIST exception previous concomitant basal cell skin cancer , previous cervical carcinoma situ Impaired cardiac function include one following : 1 . LVEF &lt; 45 % institutional LLN range ( whichever high ) determine echocardiogram Visit 1 2 . Complete leave bundle branch block 3 . Use ventricular paced cardiac pacemaker 4 . Congenital long QT syndrome family history long QT syndrome 5 . History presence significant ventricular atrial tachyarrhythmias 6 . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) 7 . QTc &gt; 450 msec screen ECG ( use QTcF formula ) . If QTc &gt; 450 msec electrolyte within normal range ( electrolyte correct patient rescreened QTc . 8 . Right bundle branch block plus leave anterior hemiblock , bifascicular block 9 . Myocardial infarction within 12 month prior Visit 1 10 . Other clinically significant heart disease ( e.g. , unstable angina , congestive heart failure uncontrolled hypertension , ) Patients severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol e.g . impairment gastrointestinal ( GI ) function , GI disease may significantly alter absorption study drug , uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>unresectable metastatic GIST</keyword>
	<keyword>1st . line treatment</keyword>
</DOC>